- Home
- ITOS
as 05-09-2025 4:00pm EST
ITeos Therapeutics Inc is a biopharmaceutical company. It designs novel product candidates with optimized pharmacologic properties to improve clinical outcomes by restoring the immune response against cancer. The company's product candidates include EOS-850 which is an Adenosine A2A receptor-specific antagonist, EOS-448 which is an ADCC-enabled, anti-TIGIT immune checkpoint blocking antibody among other drug candidates.
| Founded: | 2011 | Country: | United States |
| Employees: | N/A | City: | WATERTOWN |
| Market Cap: | 270.7M | IPO Year: | 2020 |
| Target Price: | $25.67 | AVG Volume (30 days): | 550.0K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.09 | EPS Growth: | N/A |
| 52 Week Low/High: | $4.80 - $18.75 | Next Earning Date: | 04-28-2025 |
| Revenue: | $35,000,000 | Revenue Growth: | 177.89% |
| Revenue Growth (this year): | -78.43% | Revenue Growth (next year): | 31.74% |
Latest iTeos Therapeutics Inc. News
ITOS Breaking Stock News: Dive into ITOS Ticker-Specific Updates for Smart Investing
Zacks
8 days ago
Wall Street Analysts See a 211.07% Upside in iTeos Therapeutics (ITOS): Can the Stock Really Move This High?
GlobeNewswire
11 days ago
iTeos Reports First Quarter 2025 Financial Results and Provides Business Updates
Simply Wall St.
21 days ago
Positive week for iTeos Therapeutics, Inc. (NASDAQ:ITOS) institutional investors who lost 38% over the past year
GlobeNewswire
a month ago
iTeos to Present Preclinical Data on Potential Best-In-Class Anti-TREM2 Antibody, EOS-215, and Novel PTPN1/2 Inhibitor at the American Association for Cancer Research Annual Meeting 2025
Zacks
2 months ago
Wall Street Analysts Think iTeos Therapeutics (ITOS) Could Surge 212.5%: Read This Before Placing a Bet
Simply Wall St.
2 months ago
iTeos Therapeutics Full Year 2024 Earnings: In Line With Expectations
GlobeNewswire
2 months ago
iTeos Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates
Simply Wall St.
3 months ago
We Think iTeos Therapeutics (NASDAQ:ITOS) Needs To Drive Business Growth Carefully
Compare ITOS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ITOS iTeos Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.